Pharmacometric analysis to assess the risk–benefit profile of nintedanib
Exposure-safety analyses are often a great complement to exposure-response analyses in order to drive key MIDD decisions such as therapeutic dose selection. In this example, our colleague Celine Sarr and collaborators from